{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:41:10Z","timestamp":1793810470678,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Lung Cancer is one of the four most frequent malignant neoplasms in the world, and first in mortality. In 2020, lung cancer resulted in roughly 1.8\u00a0million deaths globally. Lung cancer is a major public health problem in low and lower-middle income countries, where high rates of tobacco smoking, environmental pollution, and limited access to healthcare resources contribute to a significant burden of the disease. The objective of our review was to compare costs among available countries and identify major cost drivers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic database search was performed according to PRISMA guidelines on Web of Science, PubMed, Cochrane, EBSCO, ISPOR, and Google Scholar using a pre-defined search string. Studies were screened for eligibility and included if they provided information about the direct and indirect costs of lung cancer in low- and lower-middle-income countries. Search cut off was on August 4, 2025. The data from included studies were extracted, quantitatively synthesized, and compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 2,383 articles, 15 met the inclusion criteria. All studies were conducted in low- and lower-middle-income countries, with a time frame ranging from 2003 to 2025. Most studies estimated costs based on prevalence. Most studies reported total healthcare costs as direct costs related to lung cancer; seven studies reported on indirect costs. Total average direct costs ranged from USD 2,540.66 per patient in Nepal to USD 10,179.98 per patient in the first year of treatment in Bolivia. Indirect costs varied from USD 140,995,744.13 in Bangladesh to USD 320,427,043.97 in Vietnam for their given respective sample sizes. Cost estimates varied substantially even for the same country depending on study\u2019s analytical focus, timeframe, and other methodological considerations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In conclusion, the costs of lung cancer are substantial and increase with disease progression, encompassing both direct and indirect components. High out-of-pocket expenditures further intensify the economic burden on patients and may lead to an underestimation of the true societal costs. The lack of standardized methodologies and robust data highlights the need for further research to guide effective policy and resource allocation in LMICs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Registration: PROSPERO, ID CRD42020160370.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13690-025-01738-6","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:15:03Z","timestamp":1760343303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The economic burden of lung cancer in low- and lower-middle-income countries: a systematic review"],"prefix":"10.1186","volume":"83","author":[{"given":"Elyesa","family":"\u00dcnal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Horstick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kaifie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie R.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"1738_CR1","unstructured":"WHO. International Agency for Research on Cancer. Cancer Today, https:\/\/gco.iarc.fr\/today\/en\/dataviz\/bars?mode=cancer%26;group_populations=1%26;types=1"},{"key":"1738_CR2","doi-asserted-by":"crossref","unstructured":"Shah SC, Kayamba V, Peek RM et al. Cancer control in Low- and Middle-Income countries: is it time to consider screening? J Glob Oncol 2019; 1\u20138.","DOI":"10.1200\/JGO.18.00200"},{"key":"1738_CR3","unstructured":"John Hopkins Medicine. Lung Cancer Risk Factors, https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/lung-cancer\/lung-cancer-risk-factors"},{"key":"1738_CR4","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S2213-2600(21)00164-8","volume":"9","author":"H Ebrahimi","year":"2021","unstructured":"Ebrahimi H, Aryan Z, Saeedi Moghaddam S, et al. Global, regional, and National burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Lancet Respir Med. 2021;9:1030\u201349.","journal-title":"Lancet Respir Med"},{"key":"1738_CR5","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","volume":"397","author":"MB Reitsma","year":"2021","unstructured":"Reitsma MB, Kendrick PJ, Ababneh E, et al. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990\u20132019: a systematic analysis from the global burden of disease study 2019. Lancet. 2021;397:2337\u201360.","journal-title":"Lancet"},{"key":"1738_CR6","doi-asserted-by":"crossref","unstructured":"Theilmann M, Lemp JM, Winkler V et al. Patterns of tobacco use in low- and middle-income countries by tobacco product and sociodemographic characteristics: nationally representative survey data from 82 countries. BMJ 2022; e067582.","DOI":"10.1136\/bmj-2021-067582"},{"key":"1738_CR7","volume-title":"Clinical medicine","author":"P Kumar","year":"2005","unstructured":"Kumar P, Clark M. Respiratory diseases. Clinical medicine. Edinburgh: Elsevier Saunders; 2005."},{"key":"1738_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/ace-20-31","volume":"5","author":"J Zhang","year":"2021","unstructured":"Zhang J, Li J, Xiong S, et al. Global burden of lung cancer: implications from current evidence. Ann Cancer Epidemiol. 2021;5:4\u20134.","journal-title":"Ann Cancer Epidemiol"},{"key":"1738_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/thoraxjnl-2020-216555","volume":"77","author":"M Araghi","year":"2022","unstructured":"Araghi M, Fidler-Benaoudia M, Arnold M, et al. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 study. Thorax. 2022;77:378\u201390.","journal-title":"Thorax"},{"key":"1738_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2022.01.015","volume":"166","author":"J Zhang","year":"2022","unstructured":"Zhang J, IJzerman MJ, Oberoi J, et al. Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer. 2022;166:27\u201339.","journal-title":"Lung Cancer"},{"key":"1738_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12558-012-0212-2","volume":"4","author":"LG Sambo","year":"2012","unstructured":"Sambo LG, Dangou JM, Adebamowo C, et al. Cancer in africa: a preventable public health crisis. J Afr Cancer Afr J Cancer. 2012;4:127\u201336.","journal-title":"J Afr Cancer Afr J Cancer"},{"key":"1738_CR12","volume-title":"Guide to cancer early diagnosis","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Guide to cancer early diagnosis. Geneva: World Health Organization; 2017. https:\/\/iris.who.int\/handle\/10665\/254500. accessed 28 March 2025)."},{"key":"1738_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12992-020-00553-8","volume":"16","author":"UI Nwagbara","year":"2020","unstructured":"Nwagbara UI, Ginindza TG, Hlongwana KW. Health systems influence on the pathways of care for lung cancer in low- and middle-income countries: a scoping review. Glob Health. 2020;16:23.","journal-title":"Glob Health"},{"key":"1738_CR14","unstructured":"National Cancer Institute. PDQ Small Cell Lung Cancer Treatment. PDQ\u00ae Adult Treatment Editorial Board, https:\/\/www.cancer.gov\/types\/lung\/hp\/small-cell-lung-treatment-pdq"},{"key":"1738_CR15","unstructured":"American Cancer Society. Surgery for Non-Small Cell Lung Cancer, https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/treating-non-small-cell\/surgery.html"},{"key":"1738_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"1738_CR17","unstructured":"The Lung Ambition Alliance. Lung Cancer Screening: The Cost of Inaction. https:\/\/www.lungambitionalliance.com\/our-initiatives\/lung-cancer-screening-the-cost-of-inaction.html"},{"key":"1738_CR18","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1007\/s12325-023-02509-x","volume":"40","author":"G Bencina","year":"2023","unstructured":"Bencina G, Chami N, Hughes R, et al. Indirect costs due to lung Cancer-Related premature mortality in four European countries. Adv Ther. 2023;40:3056\u201369.","journal-title":"Adv Ther"},{"key":"1738_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s41669-017-0045-0","volume":"2","author":"A Enstone","year":"2018","unstructured":"Enstone A, Greaney M, Povsic M, et al. The economic burden of small cell lung cancer: A systematic review of the literature. PharmacoEconomics - Open. 2018;2:125\u201339.","journal-title":"PharmacoEconomics - Open"},{"key":"1738_CR20","doi-asserted-by":"publisher","first-page":"114231","DOI":"10.1016\/j.ejca.2024.114231","volume":"208","author":"K De Nijs","year":"2024","unstructured":"De Nijs K, De Koning HJ, Van Der Aalst C, et al. Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012\u20132021). Eur J Cancer. 2024;208:114231.","journal-title":"Eur J Cancer"},{"key":"1738_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40273-023-01295-2","volume":"41","author":"N Jovanoski","year":"2023","unstructured":"Jovanoski N, Abogunrin S, Di Maio D, et al. Systematic literature review to identify cost and resource use data in patients with Early-Stage Non-small cell lung cancer (NSCLC). PharmacoEconomics. 2023;41:1437\u201352.","journal-title":"PharmacoEconomics"},{"key":"1738_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1754-9485.2012.02354.x","volume":"56","author":"S Kang","year":"2012","unstructured":"Kang S, Koh E, Vinod SK, et al. Cost analysis of lung cancer management in Southwestern Sydney. J Med Imaging Radiat Oncol. 2012;56:235\u201341.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1738_CR23","first-page":"51","volume":"55","author":"\u00c7AKIR ED\u0130S E","year":"2007","unstructured":"\u00c7AKIR ED\u0130S E. The cost of lung cancer in Turkey. T\u00fcberk\u00fcloz Ve Toraks Dergisi. 2007;55:51\u20138.","journal-title":"T\u00fcberk\u00fcloz Ve Toraks Dergisi"},{"key":"1738_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vhri.2022.07.007","volume":"33","author":"M Yousefi","year":"2023","unstructured":"Yousefi M, Jalilian H, Heydari S, et al. Cost of lung cancer: A systematic review. Value Health Reg Issues. 2023;33:17\u201326.","journal-title":"Value Health Reg Issues"},{"key":"1738_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1738_CR26","unstructured":"\u00dcnal E, Louis V, B\u00e4rninghausen T et al. A systematic review of the economic burden of lung cancer in low- and low middle- income countries. PROSPERO 2020, https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42020160370"},{"key":"1738_CR27","unstructured":"the world bank. World Bank Country and Lending Groups, https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"1738_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"1738_CR29","doi-asserted-by":"publisher","first-page":"e001287","DOI":"10.1136\/rmdopen-2020-001287","volume":"6","author":"B Fautrel","year":"2020","unstructured":"Fautrel B, Boonen A, De Wit M, et al. Cost assessment of health interventions and diseases. RMD-Open. 2020;6:e001287.","journal-title":"RMD-Open"},{"key":"1738_CR30","unstructured":"Institut f\u00fcr Qualit\u00e4t. und Wirtschaftlichkeit im Gesundheitswesen. Perspektive und zu ber\u00fccksichtigende Kosten. In: Allgemeine Methoden Version 5.0. K\u00f6ln. https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_version-5-0.pdf (2017)."},{"key":"1738_CR31","unstructured":"Higgins J, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, www.training.cochrane.org\/handbook (2024)."},{"key":"1738_CR32","unstructured":"EPPI Centre. CCEMG - EPPI-Centre Cost Converter. https:\/\/eppi.ioe.ac.uk\/costconversion\/"},{"key":"1738_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy. 2010;6:51\u20139.","journal-title":"Evid Policy"},{"key":"1738_CR34","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049\u20131049.","journal-title":"BMJ"},{"key":"1738_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)\u2014Explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16:231\u201350.","journal-title":"Value Health"},{"key":"1738_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1471-2393-14-243","volume":"14","author":"L Mangham-Jefferies","year":"2014","unstructured":"Mangham-Jefferies L, Pitt C, Cousens S, et al. Cost-effectiveness of strategies to improve the utilization and provision of maternal and newborn health care in low-income and lower-middle-income countries: a systematic review. BMC Pregnancy Childbirth. 2014;14:243.","journal-title":"BMC Pregnancy Childbirth"},{"key":"1738_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/1474515114556031","volume":"15","author":"S Maru","year":"2016","unstructured":"Maru S, Byrnes J, Carrington MJ, et al. Systematic review of trial-based analyses reporting the economic impact of heart failure management programs compared with usual care. Eur J Cardiovasc Nurs. 2016;15:82\u201390.","journal-title":"Eur J Cardiovasc Nurs"},{"key":"1738_CR38","doi-asserted-by":"publisher","first-page":"e0168447","DOI":"10.1371\/journal.pone.0168447","volume":"11","author":"N Zakiyah","year":"2016","unstructured":"Zakiyah N, Van Asselt ADI, Roijmans F, et al. Economic evaluation of family planning interventions in Low- and Middle-Income Countries; A systematic review. PLoS ONE. 2016;11:e0168447.","journal-title":"PLoS ONE"},{"key":"1738_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fpubh.2019.00160","volume":"7","author":"SR Khatiwoda","year":"2019","unstructured":"Khatiwoda SR, Dhungana RR, Sapkota VP, et al. Estimating the direct cost of cancer in nepal: A Cross-Sectional study in a tertiary cancer hospital. Front Public Health. 2019;7:160.","journal-title":"Front Public Health"},{"key":"1738_CR40","doi-asserted-by":"crossref","unstructured":"Hoang Anh PT, Thu LT, Ross H et al. Direct and indirect costs of smoking in Vietnam. Tob Control 2014; tobaccocontrol-2014-051821.","DOI":"10.1136\/tobaccocontrol-2014-051821"},{"key":"1738_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/tc.2007.020396","volume":"16","author":"H Ross","year":"2007","unstructured":"Ross H, Trung DV, Phu VX. The costs of smoking in vietnam: the case of inpatient care. Tob Control. 2007;16:405\u20139.","journal-title":"Tob Control"},{"key":"1738_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.canep.2017.12.013","volume":"53","author":"A Pearce","year":"2018","unstructured":"Pearce A, Sharp L, Hanly P, et al. Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison. Cancer Epidemiol. 2018;53:27\u201334.","journal-title":"Cancer Epidemiol"},{"key":"1738_CR43","unstructured":"Fenniche S, Fekih LE, Abdelghaffar HB et al. Chimioth\u00e9rapie palliative des cancers bronchiques non \u00e0 petites cellules (CBNPC) m\u00e9tastatiques en Tunisie: Etude prospective du co\u00fbt et impact sur la qualit\u00e9 de vie. Tunis Med 89."},{"key":"1738_CR44","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.7314\/APJCP.2012.13.4.1547","volume":"13","author":"N Tachfouti","year":"2012","unstructured":"Tachfouti N, Belkacemi Y, Raherison C, et al. First data on direct costs of lung cancer management in Morocco. Asian Pac J Cancer Prev. 2012;13:1547\u201351.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1738_CR45","doi-asserted-by":"publisher","first-page":"e1282","DOI":"10.1016\/S2214-109X(20)30311-9","volume":"8","author":"A Pichon-Riviere","year":"2020","unstructured":"Pichon-Riviere A, Alcaraz A, Palacios A, et al. The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study. Lancet Glob Health. 2020;8:e1282\u201394.","journal-title":"Lancet Glob Health"},{"key":"1738_CR46","doi-asserted-by":"publisher","first-page":"988","DOI":"10.26719\/2018.24.10.988","volume":"24","author":"C Harizi","year":"2018","unstructured":"Harizi C, Bellali H, Hchaichi A, et al. Cost Estimation of medical care management of lung cancer in Tunisia. East Mediterr Health J. 2018;24:988\u201393.","journal-title":"East Mediterr Health J"},{"key":"1738_CR47","doi-asserted-by":"crossref","unstructured":"Kyaing NN. October. Tobacco economics in Myanmar. WHO Tob Control Papers, 1 2003.","DOI":"10.1596\/13633"},{"key":"1738_CR48","unstructured":"Faruque G, Ahmed M, Huq I et al. March. The economic cost of tobacco use in bangladesh: A health cost approach. Bangladesh Cancer Soc, 1 2020."},{"key":"1738_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/13696998.2024.2435750","volume":"28","author":"KA Wahab","year":"2025","unstructured":"Wahab KA, Hassan A, Morsi A, et al. The indirect costs of five cancers in egypt: years of life lost and productivity costs. J Med Econ. 2025;28:36\u201343.","journal-title":"J Med Econ"},{"key":"1738_CR50","doi-asserted-by":"publisher","first-page":"e082025","DOI":"10.1136\/bmjopen-2023-082025","volume":"14","author":"O Rashdan","year":"2024","unstructured":"Rashdan O. Estimating the indirect economic burden of cancer in jordan: a retrospective observational study. BMJ Open. 2024;14:e082025.","journal-title":"BMJ Open"},{"key":"1738_CR51","doi-asserted-by":"publisher","first-page":"100428","DOI":"10.1016\/j.jcpo.2023.100428","volume":"37","author":"I El Harch","year":"2023","unstructured":"El Harch I, Guendaoui S, Charkaoui M, et al. Economic burden of lung cancer in morocco: A cost of illness study. J Cancer Policy. 2023;37:100428.","journal-title":"J Cancer Policy"},{"key":"1738_CR52","doi-asserted-by":"publisher","first-page":"e044969","DOI":"10.1136\/bmjopen-2020-044969","volume":"11","author":"AO Olumide","year":"2021","unstructured":"Olumide AO, Shmueli A, Omotade OO, et al. Economic costs of terminal care for selected non-communicable diseases from a healthcare perspective: a review of mortality records from a tertiary hospital in Nigeria. BMJ Open. 2021;11:e044969.","journal-title":"BMJ Open"},{"key":"1738_CR53","doi-asserted-by":"publisher","first-page":"1179173X2412723","DOI":"10.1177\/1179173X241272385","volume":"17","author":"D Mwai","year":"2024","unstructured":"Mwai D, Gathecha G, Njuguna D, et al. The economic costs of tobacco related illnesses in Kenya. Tob Use Insights. 2024;17:1179173X241272385.","journal-title":"Tob Use Insights"},{"key":"1738_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12916-015-0433-1","volume":"13","author":"The ACTION Study Group","year":"2015","unstructured":"The ACTION Study Group. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast asia: results from a longitudinal study in eight countries. BMC Med. 2015;13:190.","journal-title":"BMC Med"},{"key":"1738_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela Cruz CS. Lung cancer 2020. Clin Chest Med. 2020;41:1\u201324.","journal-title":"Clin Chest Med"},{"key":"1738_CR56","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1738_CR57","doi-asserted-by":"crossref","unstructured":"Global Tobacco Economics Consortium. The health, poverty, and financial consequences of a cigarette price increase among 500 million male smokers in 13 middle income countries: compartmental model study. BMJ 2018; k1162.","DOI":"10.1136\/bmj.k1162"},{"key":"1738_CR58","doi-asserted-by":"crossref","unstructured":"Jha P, Khan J, Mishra S et al. Raising taxes key to accelerate tobacco control in South Asia. BMJ 2017; j1176.","DOI":"10.1136\/bmj.j1176"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-025-01738-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-025-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:15:14Z","timestamp":1760343314000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-025-01738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1186\/s13690-025-01738-6","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}